Ivabradin Teva (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a lower resting heart rate without decreasing the strength of cardiac contraction.

The appropriate dose of Ivabradin Teva is determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and any concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability, following local prescribing guidelines.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is not classified for use in these populations. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractility and blood pressure, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Ivabradin Teva should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf‑life.

The medication is taken orally, usually with a glass of water. It is typically administered twice daily, but the exact schedule and timing are set by the prescribing physician based on the individual’s clinical response and heart‑rate targets.

The most serious adverse events include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may affect retinal function. Patients should be monitored regularly for these events, and therapy should be discontinued if they occur.

Ivabradin Teva is contraindicated in patients with a resting heart rate below 50 bpm, those with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or advanced atrioventricular block without a pacemaker. It should also be avoided in individuals with known hypersensitivity to ivabradine.